GHRH receptor agonist. Stimulates pituitary somatotrophs to release endogenous growth hormone in pulsatile fashion.
Reference facts
- Also known as
- GHRH (1-29), GRF 1-29
- Category
- Growth Hormone & Ghrelin
- Mechanism of action
- GHRH receptor agonist. Stimulates pituitary somatotrophs to release endogenous growth hormone in pulsatile fashion.
- Targets
- GHRHR
- Indications under research or approved
- Pediatric growth hormone deficiency (formerly approved as Geref); off-label adult anti-aging research
- Regulatory status (reference entry)
- FDA approval withdrawn 2008 (commercial reasons); compounded as research peptide
- Half-life
- ~10–20 minutes
- Sequence
- YADAIFTNSYRKVLGQLSARKLLQDIMSR
- Sequence notes
- 29-residue N-terminal fragment of human growth hormone-releasing hormone (GHRH 1-29 NH2). C-terminal amide.
- Molecular weight (Da)
- 3358
- PDB accession
- 1HOZ
- Originator / sponsor
- Originally Serono (Geref); now compounding pharmacies
- First reported
- 1980
- Origin
- Synthesized from the GHRH sequence isolated by Roger Guillemin and Wylie Vale (Nobel laureates).
Primary References
Explore research articles about Sermorelin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.